Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Freeze-Dried, Not Frozen: Lyophilized Mesenchymal Stromal Cell-Derived Extracellular Vesicles and Therapeutic Function in Neuroinflammatory Models.

Ashley JR., Collier AM., Olson SD., Cox CS.

Animal Study on Immune Modulation, published in J Am Coll Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Am Coll Surg (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41051108
PMCID
PMC12704670
DOI
10.1097/XCS.0000000000001591

Abstract (original English)

Background Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) offer a promising acellular therapy for immune modulation, but clinical translation is hindered by variability and storage constraints. Lyophilization (freeze-drying) could enable shelf-stable EV therapeutics, although its effects on biological activity remain incompletely defined. Study design We compared the immunomodulatory effects of frozen and lyophilized EVs from bone marrow (BM), adipose tissue (AD), and umbilical cord (UC) MSCs using lipopolysaccharide-stimulated rodent splenocytes and microglial models and human peripheral blood mononuclear cells (PBMCs). Variables included batch scale (small vs large), cytokine priming, and MSC source. Tumor necrosis factor alpha (TNF-α) secretion was measured as a marker of inflammation. Results Lyophilized small-batch BM-derived MSC EVs consistently suppressed TNF-α in rodent splenocytes and microglia. Large-batch and cytokine-stimulated EVs showed more variable responses. UC- and AD-derived EVs elicited inconsistent effects in rodent splenocytes. In contrast, lyophilized UC- and AD-derived EVs on human PBMCs exhibited reproducible suppression of TNF-α across 3 donors. Conclusions Lyophilized MSC-EVs-particularly from UC MSCs-retain immunomodulatory function and perform comparably or better than frozen counterparts. Although rodent models revealed signifi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Extracellular VesiclesFreeze DryingAnimalsMesenchymal Stem CellsHumansAdipose TissueLeukocytes, MononuclearTumor Necrosis Factor-alphaRatsNeuroinflammatory Diseases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research